search
Back to results

Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles

Primary Purpose

Infertility, Female

Status
Not yet recruiting
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Letrozol (Femara, Novartis)
Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)
highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)
highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
Sponsored by
Menoufia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility, Female

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  1. Women aged between 20-35 years
  2. Body mass index ≤ 30
  3. Primary or secondary infertility for ≥1 year due to PCOS (diagnosed based on Rotterdam criteria which require the presence of two of the following: Oligo\an ovulation , hyperandrogenism, polycystic ovaries on ultrasound)
  4. Failure to achieve ovulation after clomiphene citrate treatment at a dose of 150mg daily (if the patient can tolerate this dose) for 5 days for 3 cycles or only 100 mg daily for the same duration (if she can't tolerate higher dose)
  5. Failure to achieve pregnancy after 3 cycles of ultrasound indicated ovulation with clomiphene citrate treatment at a dose of 100mg or 150mg daily.
  6. Day-2 follicle-stimulating hormone less than 12 IU/ml
  7. Normal serum prolactin and thyroid function
  8. Normal uterine cavity
  9. At least one patent tube
  10. Male partner with normal semen count and motility according to WHO criteria

Exclusion Criteria:

  1. Male factor infertility
  2. Bilateral tubal block
  3. Uncontrolled thyroid dysfunction
  4. Uterine factor of infertility.
  5. Known cases with endometriosis.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm Type

    Active Comparator

    Active Comparator

    Active Comparator

    Active Comparator

    Arm Label

    GROUP 1

    GROUP 2

    GROUP 3

    GROUP 4

    Arm Description

    GROUP 1: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.

    GROUP 2: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test

    Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.

    Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test

    Outcomes

    Primary Outcome Measures

    Occurrence of ovulation
    US detection of one or more follicles of 18mm or more
    Number of dominant follicles
    US detection of follicles >18mm
    Endometrial thickness
    US assessment of endometrial thickness

    Secondary Outcome Measures

    Occurrence of pregnancy which will be subdivided into: chemical pregnancy or clinical pregnancy
    type of pregnancy
    Total number of patients getting pregnant after each treatment cycle in each group
    record occurrence of pregnancy
    Number of cycles cancelled in each group
    detect cycle cancellation
    Number of patients developing OHSS in each group
    detect ovarian hyperstimulation syndrom
    Number of patients having multiple pregnancy in each group
    detect multiple pregnancy
    Number of patients ended by 1st trimester miscarriage in each group
    detect miscarriage
    Side effects recorded in each group
    record side effects that patients complaint

    Full Information

    First Posted
    May 2, 2022
    Last Updated
    May 2, 2022
    Sponsor
    Menoufia University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05362799
    Brief Title
    Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles
    Official Title
    Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2022
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    June 1, 2022 (Anticipated)
    Primary Completion Date
    December 31, 2023 (Anticipated)
    Study Completion Date
    December 31, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Menoufia University

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The aim of this study will be to compare between 4 different induction protocols in women who: Failed to achieve ovulation after clomiphene citrate treatment at a dose of 150mg daily (if the patient can tolerate this dose) for 5 days for 3 cycles or only 100 mg daily for the same duration (if she can't tolerate higher dose) Failed to achieve pregnancy after 3 cycles of ultrasound indicated ovulation with clomiphene citrate treatment at a dose of 100mg or 150mg daily. All induction protocols will be carried out in non-IVF cycles, and continued for 3 cycles or until pregnancy whichever will be earlier.
    Detailed Description
    The study will include 4 treatment groups: GROUP 1: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. GROUP 2: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test GROUP 3: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. GROUP 4: Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test For follow up:US folliculometry will be done on Day 8 in all groups. Further appointments for folliculometry will be given upon the response. Dominant follicle will be diagnosed on Day 8 if the average follicular diameter is 12mm or more (taken in 2 perpendicular diameters) then follow up will be continued till the diameter reaching 18-22mm so that triggering ovulation will be carried out by administration of human chorionic gonadotrophins (Epifasi 5000 IU, ampoule, EIPICO pharmaceuticals, Egypt). All women will be advised to receive the injection within 12 hours of the last follicular measurement. Women will be advised to have unprotected intercourse 24-36h following hCG injection. Serum β-hCG will be measured after 2 weeks to check for pregnancy and US will be performed after 2-4 weeks from B-hCG results to confirm the presence of pregnancy. Each couple will be involved in the study for 3 treatment cycles if pregnancy will not occur but still having the option not to continue in our study where we will manage them outside the study protocol. Women who will get pregnant will be followed for 12w gestational age for possible detection of 1st trimester abortion.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Infertility, Female

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    176 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    GROUP 1
    Arm Type
    Active Comparator
    Arm Description
    GROUP 1: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
    Arm Title
    GROUP 2
    Arm Type
    Active Comparator
    Arm Description
    GROUP 2: Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
    Arm Title
    GROUP 3
    Arm Type
    Active Comparator
    Arm Description
    Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
    Arm Title
    GROUP 4
    Arm Type
    Active Comparator
    Arm Description
    Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
    Intervention Type
    Drug
    Intervention Name(s)
    Letrozol (Femara, Novartis)
    Intervention Description
    Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days.
    Intervention Type
    Drug
    Intervention Name(s)
    Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt)
    Intervention Description
    Participants of this group will receive Letrozol (Femara, Novartis) at a dose of 2.5mg twice daily starting from day 3 of the cycle for 5 days. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
    Intervention Type
    Drug
    Intervention Name(s)
    highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)
    Intervention Description
    Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry.
    Intervention Type
    Drug
    Intervention Name(s)
    highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland) combined with metformin
    Intervention Description
    Participants of this group will receive highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland.) at a dose of 75IU S.C or IM starting from day 3 of the cycle for 5 days. Readjustment of the dose will occur upon the results of day 8 folliculometry. Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt) 500 mg twice daily will also started from day 3 till the date of doing pregnancy test
    Primary Outcome Measure Information:
    Title
    Occurrence of ovulation
    Description
    US detection of one or more follicles of 18mm or more
    Time Frame
    18 month
    Title
    Number of dominant follicles
    Description
    US detection of follicles >18mm
    Time Frame
    18 month
    Title
    Endometrial thickness
    Description
    US assessment of endometrial thickness
    Time Frame
    18 months
    Secondary Outcome Measure Information:
    Title
    Occurrence of pregnancy which will be subdivided into: chemical pregnancy or clinical pregnancy
    Description
    type of pregnancy
    Time Frame
    18 months
    Title
    Total number of patients getting pregnant after each treatment cycle in each group
    Description
    record occurrence of pregnancy
    Time Frame
    18 months
    Title
    Number of cycles cancelled in each group
    Description
    detect cycle cancellation
    Time Frame
    18 months
    Title
    Number of patients developing OHSS in each group
    Description
    detect ovarian hyperstimulation syndrom
    Time Frame
    18 months
    Title
    Number of patients having multiple pregnancy in each group
    Description
    detect multiple pregnancy
    Time Frame
    18 months
    Title
    Number of patients ended by 1st trimester miscarriage in each group
    Description
    detect miscarriage
    Time Frame
    18 months
    Title
    Side effects recorded in each group
    Description
    record side effects that patients complaint
    Time Frame
    18 months

    10. Eligibility

    Sex
    Female
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Women aged between 20-35 years Body mass index ≤ 30 Primary or secondary infertility for ≥1 year due to PCOS (diagnosed based on Rotterdam criteria which require the presence of two of the following: Oligo\an ovulation , hyperandrogenism, polycystic ovaries on ultrasound) Failure to achieve ovulation after clomiphene citrate treatment at a dose of 150mg daily (if the patient can tolerate this dose) for 5 days for 3 cycles or only 100 mg daily for the same duration (if she can't tolerate higher dose) Failure to achieve pregnancy after 3 cycles of ultrasound indicated ovulation with clomiphene citrate treatment at a dose of 100mg or 150mg daily. Day-2 follicle-stimulating hormone less than 12 IU/ml Normal serum prolactin and thyroid function Normal uterine cavity At least one patent tube Male partner with normal semen count and motility according to WHO criteria Exclusion Criteria: Male factor infertility Bilateral tubal block Uncontrolled thyroid dysfunction Uterine factor of infertility. Known cases with endometriosis.

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles

    We'll reach out to this number within 24 hrs